At a glance
ClinicalIndex Comparison RecordN/ACompleted· 827 enrolled
Drug / intervention
Vagus Nerve Stimulation (VNS) Therapydevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CORE-VNS: Comprehensive Outcomes Registry in Subjects With Epilepsy Treated With Vagus Nerve Stimulation Therapy
In Brief
An observational study evaluating Vagus Nerve Stimulation (VNS) Therapy for Epilepsy and 2 related conditions. Completed, enrolled 827 participants across 62 sites in 16 countries.
Detailed Summary
Multicenter global post-market registry of subjects diagnosed with drug resistant epilepsy and treated with the VNS Therapy System.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy, Seizures, Drug Resistant Epilepsy
CountriesAustralia, Austria, Belgium, Brazil, Canada, China, India, Israel, Italy, Japan, Netherlands, Poland, Portugal, Saudi Arabia, United Kingdom, United States
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartFeb 2018
First PostedMay 2018
Primary CompletionSep 2024
TodayJul 2026
First PostedMay 18, 2018
Enrollment StartFeb 5, 2018
Primary CompletionSep 11, 2024
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 8.1 years ago
Interventions
Vagus Nerve Stimulation (VNS) Therapydevice
The VNS Therapy System is a commercially available device that will be used by licensed medical practitioners trained in the use of VNS Therapy, per the practitioners' medical judgement.